Which has better valuation and earnings, ANIK or OKYO?

OKYO Pharma has lower revenue, but higher earnings than Anika Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anika Therapeutics $112.82M 2.47 -$10.88M -$0.27 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Which has higher earnings and valuation, OKYO or PYXS?

OKYO Pharma has higher earnings, but lower revenue than Pyxis Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Pyxis Oncology $13.86M 20.04 -$79.62M -$1.41 N/A

Is OKYO or PYXS more profitable?

OKYO Pharma's return on equity of 0.00% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Pyxis Oncology N/A -215.23% -112.19%

Which has preferable valuation and earnings, OKYO or CYPH?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Cypherpunk Technologies N/A N/A $4.82M $0.56 6.43

Is OKYO or CYPH more profitable?

OKYO Pharma's return on equity of 0.00% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Cypherpunk Technologies N/A -20.76% -19.48%

Which has better valuation and earnings, OKYO or ACIU?

OKYO Pharma has higher earnings, but lower revenue than AC Immune. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A AC Immune $4.31M 62.10 -$85.03M -$0.54 N/A

Is OKYO or ACIU more profitable?

OKYO Pharma has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. OKYO Pharma's return on equity of 0.00% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A AC Immune -245.32% -100.17% -28.36%

Which has stronger earnings and valuation, OKYO or STRO?

OKYO Pharma has higher earnings, but lower revenue than Sutro Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OKYO Pharma N/A N/A -$8.95M N/A N/A Sutro Biopharma $102.48M 2.48 -$191.09M -$11.97 N/A

Is OKYO or STRO more profitable?

OKYO Pharma has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Company Net Margins Return on Equity Return on Assets OKYO Pharma N/A N/A N/A Sutro Biopharma -395.25% N/A -88.12%

OKYO Pharma (OKYO) Competitors

$1.36 +0.04 (+3.03%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+1.10%)

As of 09/18/2026 07:30 PM Eastern

Compare

OKYO vs. ANIK, PYXS, CYPH, ACIU, and STRO

Should you buy OKYO Pharma stock or one of its competitors? OKYO Pharma's main competitors and comparable companies include Anika Therapeutics (ANIK), Pyxis Oncology (PYXS), Cypherpunk Technologies (CYPH), AC Immune (ACIU), and Sutro Biopharma (STRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does OKYO Pharma compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

OKYO Pharma has lower revenue, but higher earnings than Anika Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.47	-$10.88M	-$0.27	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

Anika Therapeutics currently has a consensus target price of $22.00, suggesting a potential upside of 5.72%. OKYO Pharma has a consensus target price of $5.67, suggesting a potential upside of 316.67%. Given OKYO Pharma's higher probable upside, analysts plainly believe OKYO Pharma is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Anika Therapeutics had 3 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for Anika Therapeutics and 0 mentions for OKYO Pharma. Anika Therapeutics' average media sentiment score of 0.80 beat OKYO Pharma's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Anika Therapeutics	Positive
OKYO Pharma	Neutral

OKYO Pharma has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat OKYO Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
OKYO Pharma	N/A	N/A	N/A

Anika Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market.

Summary

Anika Therapeutics beats OKYO Pharma on 9 of the 14 factors compared between the two stocks.

How does OKYO Pharma compare to Pyxis Oncology?

OKYO Pharma (NASDAQ:OKYO) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

OKYO Pharma has higher earnings, but lower revenue than Pyxis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Pyxis Oncology	$13.86M	20.04	-$79.62M	-$1.41	N/A

In the previous week, Pyxis Oncology had 3 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for Pyxis Oncology and 0 mentions for OKYO Pharma. Pyxis Oncology's average media sentiment score of 0.74 beat OKYO Pharma's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
OKYO Pharma	Neutral
Pyxis Oncology	Positive

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

OKYO Pharma's return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Pyxis Oncology	N/A	-215.23%	-112.19%

OKYO Pharma presently has a consensus target price of $5.67, suggesting a potential upside of 316.67%. Pyxis Oncology has a consensus target price of $8.75, suggesting a potential upside of 162.76%. Given OKYO Pharma's higher probable upside, research analysts plainly believe OKYO Pharma is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

OKYO Pharma has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

Summary

Pyxis Oncology beats OKYO Pharma on 7 of the 12 factors compared between the two stocks.

How does OKYO Pharma compare to Cypherpunk Technologies?

OKYO Pharma (NASDAQ:OKYO) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

OKYO Pharma has a beta of 0.03, meaning that its share price is 97% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

In the previous week, Cypherpunk Technologies had 3 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for Cypherpunk Technologies and 0 mentions for OKYO Pharma. Cypherpunk Technologies' average media sentiment score of 0.28 beat OKYO Pharma's score of 0.00 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
OKYO Pharma	Neutral
Cypherpunk Technologies	Neutral

OKYO Pharma presently has a consensus target price of $5.67, indicating a potential upside of 316.67%. Cypherpunk Technologies has a consensus target price of $4.90, indicating a potential upside of 36.11%. Given OKYO Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe OKYO Pharma is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	6.43

OKYO Pharma's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Cypherpunk Technologies	N/A	-20.76%	-19.48%

Summary

OKYO Pharma beats Cypherpunk Technologies on 6 of the 11 factors compared between the two stocks.

How does OKYO Pharma compare to AC Immune?

OKYO Pharma (NASDAQ:OKYO) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

OKYO Pharma has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. OKYO Pharma's return on equity of 0.00% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
AC Immune	-245.32%	-100.17%	-28.36%

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

OKYO Pharma has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

OKYO Pharma presently has a consensus price target of $5.67, suggesting a potential upside of 316.67%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 185.17%. Given OKYO Pharma's higher probable upside, analysts plainly believe OKYO Pharma is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
AC Immune	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

OKYO Pharma has higher earnings, but lower revenue than AC Immune.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
AC Immune	$4.31M	62.10	-$85.03M	-$0.54	N/A

In the previous week, OKYO Pharma's average media sentiment score of 0.00 equaled AC Immune'saverage media sentiment score.

Company	Overall Sentiment
OKYO Pharma	Neutral
AC Immune	Neutral

Summary

OKYO Pharma beats AC Immune on 6 of the 9 factors compared between the two stocks.

How does OKYO Pharma compare to Sutro Biopharma?

OKYO Pharma (NASDAQ:OKYO) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

OKYO Pharma has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

In the previous week, Sutro Biopharma had 4 more articles in the media than OKYO Pharma. MarketBeat recorded 4 mentions for Sutro Biopharma and 0 mentions for OKYO Pharma. Sutro Biopharma's average media sentiment score of 1.14 beat OKYO Pharma's score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
OKYO Pharma	Neutral
Sutro Biopharma	Positive

3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

OKYO Pharma has higher earnings, but lower revenue than Sutro Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A
Sutro Biopharma	$102.48M	2.48	-$191.09M	-$11.97	N/A

OKYO Pharma has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%.

Company	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
Sutro Biopharma	-395.25%	N/A	-88.12%

OKYO Pharma presently has a consensus price target of $5.67, indicating a potential upside of 316.67%. Sutro Biopharma has a consensus price target of $47.30, indicating a potential upside of 208.34%. Given OKYO Pharma's higher possible upside, equities research analysts clearly believe OKYO Pharma is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Sutro Biopharma beats OKYO Pharma on 8 of the 13 factors compared between the two stocks.

Get OKYO Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKYO vs. The Competition

Export

Metric	OKYO Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$71.37M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	N/A	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	4.53	15.45	10.46	6.33
Net Income	-$8.95M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-2.86%	-1.21%	0.59%	1.12%
1 Month Performance	-10.53%	-3.29%	-1.74%	-2.39%
1 Year Performance	-31.31%	37.74%	18.13%	5.35%

OKYO Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKYO OKYO Pharma	2.3874 of 5 stars	$1.36 +3.0%	$5.67 +316.7%	-31.3%	$71.37M	N/A	N/A	5
ANIK Anika Therapeutics	3.2633 of 5 stars	$20.99 +0.4%	$21.00 +0.0%	+133.8%	$280.85M	$112.82M	N/A	235	News Coverage Analyst Forecast
PYXS Pyxis Oncology	3.4195 of 5 stars	$3.36 +0.9%	$8.75 +160.4%	+48.0%	$280.26M	$13.86M	N/A	56
CYPH Cypherpunk Technologies	2.9254 of 5 stars	$2.59 +16.7%	$4.90 +89.2%	+1,142.2%	$279.10M	N/A	4.63	40	News Coverage Analyst Upgrade
ACIU AC Immune	2.2414 of 5 stars	$2.71 +1.1%	$7.50 +176.8%	+7.3%	$275.80M	$4.31M	N/A	106	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKYO) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OKYO Pharma (OKYO) Competitors

OKYO vs. ANIK, PYXS, CYPH, ACIU, and STRO

How does OKYO Pharma compare to Anika Therapeutics?

Summary

How does OKYO Pharma compare to Pyxis Oncology?

Summary

How does OKYO Pharma compare to Cypherpunk Technologies?

Summary

How does OKYO Pharma compare to AC Immune?

Summary

How does OKYO Pharma compare to Sutro Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OKYO Pharma (OKYO) Competitors

OKYO vs. ANIK, PYXS, CYPH, ACIU, and STRO

How does OKYO Pharma compare to Anika Therapeutics?

Do insiders and institutionals hold more shares of ANIK or OKYO?

Which has better valuation and earnings, ANIK or OKYO?

Do analysts recommend ANIK or OKYO?

Does the media favor ANIK or OKYO?

Is ANIK or OKYO more profitable?

Which has more volatility & risk, ANIK or OKYO?

Summary

How does OKYO Pharma compare to Pyxis Oncology?

Which has higher earnings and valuation, OKYO or PYXS?

Does the media prefer OKYO or PYXS?

Do insiders & institutionals hold more shares of OKYO or PYXS?

Is OKYO or PYXS more profitable?

Do analysts rate OKYO or PYXS?

Which has more risk & volatility, OKYO or PYXS?

Summary

How does OKYO Pharma compare to Cypherpunk Technologies?

Do institutionals & insiders have more ownership in OKYO or CYPH?

Which has more risk & volatility, OKYO or CYPH?

Does the media prefer OKYO or CYPH?

Do analysts prefer OKYO or CYPH?

Which has preferable valuation and earnings, OKYO or CYPH?

Is OKYO or CYPH more profitable?

Summary

How does OKYO Pharma compare to AC Immune?

Is OKYO or ACIU more profitable?

Do institutionals and insiders hold more shares of OKYO or ACIU?

Which has more risk and volatility, OKYO or ACIU?

Do analysts prefer OKYO or ACIU?

Which has better valuation and earnings, OKYO or ACIU?

Does the media prefer OKYO or ACIU?

Summary

How does OKYO Pharma compare to Sutro Biopharma?

Which has more volatility & risk, OKYO or STRO?

Does the media prefer OKYO or STRO?

Do institutionals & insiders believe in OKYO or STRO?

Which has stronger earnings and valuation, OKYO or STRO?

Is OKYO or STRO more profitable?

Do analysts recommend OKYO or STRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO vs. The Competition

OKYO Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools